# A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

> **NCT06195930** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 106 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Vericiguat (BAY1021189) 5 mg

## Key facts

- **NCT ID:** NCT06195930
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-18
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-07-29
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195930, "A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06195930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*